Neuren Pharmaceuticals (ASX:NEU) said its partner Acadia Pharmaceuticals reported first-quarter net sales of $84.6 million in the US for its Rett syndrome drug, Daybue, according to a Thursday Australian bourse filing.
The figure represents an 11% increase from last year, the filing said.
Acadia, the company's partner for the development and commercialization of the drug, retained the net sales guidance for the current year of between $380 million and $405 million for the US market.
The company expects US royalties of AU$62 to AU$67 million for the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.